MYCN and neuroendocrine neoplasm: Previous studies have reported that MYCN, an oncogenic regulator involved in multiple neuroendocrine tumors, undergoes amplification and is overexpressed in 40% of NEPC cases, compared with only 5% incidence in prostate adenocarcinoma cases.